Herein, we demonstrate the ability to potentiate CDK4/6i response by inducing maladaptive levels of CIN and irreversible cell fates in models of both triple negative breast cancer (TNBC) and ER+ breast cancer. The gene discussed is CDK4; the disease is breast carcinoma.